blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1294770

EP1294770 - HUMAN IGM ANTIBODIES WITH THE CAPABILITY OF INDUCING REMYELINATION, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF PARTICULARLY IN THE CENTRAL NERVOUS SYSTEM [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.10.2012
Database last updated on 16.11.2024
Most recent event   Tooltip30.05.2014Lapse of the patent in a contracting state
New state(s): LU		published on 02.07.2014  [2014/27]
Applicant(s)For all designated states
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
200 First Street S.W.
Rochester, MN 55905 / US
[N/P]
Former [2003/13]For all designated states
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
200 First Street S.W.
Rochester, MN 55905 / US
Inventor(s)01 / RODRIGUEZ, Moses
2402 Hillside Lane, S.W.
Rochester, MN 55902 / US
02 / MILLER, David, J.
224 Cretney Street
Ridgeway, Wisconsin 53582 / US
03 / PEASE, Larry, R.
1708 Northern Viola Lane, N.E.
Rochester, MN 55906 / US
 [2003/39]
Former [2003/27]01 / RODRIGUEZ, Moses
2402 Hillside Lane, S.W.
Rochester, MN 55902 / US
02 / MILLER, David, J.
752 Odana Lane
Madison, Wisconsin 53711 / US
03 / PEASE, Larry, R.
1708 Northern Viola Lane, N.E.
Rochester, MN 55906 / US
Former [2003/13]01 / RODRIGUEZ, Moses
2402 Hillside Lane, S.W.
Rochester, MN 55902 / US
02 / MILLER, David, J.
1501 Fallston Road
Fallston, MD 21047 / US
03 / PEASE, Larry, R.
1708 Northern Viola Lane, N.E.
Rochester, MN 55906 / US
Representative(s)Mercer, Christopher Paul, et al
Carpmaels & Ransford LLP
One Southampton Row
London
WC1B 5HA / GB
[N/P]
Former [2003/13]Mercer, Christopher Paul, et al
Carpmaels & Ransford 43, Bloomsbury Square
London WC1A 2RA / GB
Application number, filing date00948498.130.05.2000
[2003/13]
WO2000US14902
Priority number, dateUS2000056835110.05.2000         Original published format: US 568351
[2003/13]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO0185797
Date:15.11.2001
Language:EN
[2001/46]
Type: A1 Application with search report 
No.:EP1294770
Date:26.03.2003
Language:EN
The application published by WIPO in one of the EPO official languages on 15.11.2001 takes the place of the publication of the European patent application.
[2003/13]
Type: B1 Patent specification 
No.:EP1294770
Date:07.12.2011
Language:EN
[2011/49]
Search report(s)International search report - published on:EP15.11.2001
ClassificationIPC:C07K16/06, C07K16/18, A61K39/395, G01N33/53, A61P25/02, C12N15/13, C12N5/10, C12N1/19, C12N1/21, A61K47/48, C07K16/46, C12N15/63, A61K48/00
[2010/35]
CPC:
C07K16/2896 (EP); A61P25/00 (EP); A61P25/02 (EP);
A61P25/16 (EP); A61P25/28 (EP); A61P31/04 (EP);
A61P31/12 (EP); A61P43/00 (EP); C07K16/00 (EP);
C12N5/0622 (EP); A61K2039/505 (EP); A61K35/12 (EP);
C07K2317/21 (EP); C07K2317/24 (EP); C07K2319/00 (EP) (-)
Former IPC [2003/13]C07K16/06, C07K16/18, A61K39/395, G01N33/53, A61P25/02, C12N5/08, C12N15/13, C12N5/06, C12N5/10, C12N1/19, C12N1/21, A61K47/48, C07K16/46, C12N15/63, A61K48/00
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2003/13]
TitleGerman:MENSCHLICHE IGM ANTIKÖRPER, WELCHE DIE FÄHIGKEIT BESITZEN, DEN WIEDERAUFBAU DER MYELINSTRUKTUR ZU INDUZIEREN UND DEREN DIAGNOSTISCHE UND THERAPEUTISCHE ANWENDUNG IM ZENTRALEN NERVENSYSTEM[2009/14]
English:HUMAN IGM ANTIBODIES WITH THE CAPABILITY OF INDUCING REMYELINATION, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF PARTICULARLY IN THE CENTRAL NERVOUS SYSTEM[2003/13]
French:ANTICORPS IGM HUMAINS PERMETTANT DE DECLENCHER LA REMYELINISATION, ET UTILISATIONS DE CEUX-CI A DES FINS DIAGNOSTIQUES ET THERAPEUTIQUES, PLUS PARTICULIEREMENT DANS LE SYSTEME NERVEUX CENTRAL[2003/13]
Former [2003/13]MENSCHLICHE IGM ANTIKÖRPER, WELCHE DIE FÄHIGKIET BESITZEN, DEN WIEDERAUFBAU DER MYELINSTRUKTUR ZU INDUZIEREN UND DEREN DIAGNOSTISCHE UND THERAPEUTISCHE ANWENDUNG IM ZENTRALEN NERVENSYSTEM
Entry into regional phase09.12.2002National basic fee paid 
09.12.2002Designation fee(s) paid 
09.12.2002Examination fee paid 
Examination procedure10.12.2001Request for preliminary examination filed
International Preliminary Examining Authority: US
09.12.2002Amendment by applicant (claims and/or description)
09.12.2002Examination requested  [2003/13]
14.07.2005Despatch of a communication from the examining division (Time limit: M06)
28.02.2006Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
10.03.2006Reply to a communication from the examining division
14.05.2007Despatch of a communication from the examining division (Time limit: M06)
15.11.2007Reply to a communication from the examining division
13.10.2008Despatch of a communication from the examining division (Time limit: M04)
05.02.2009Reply to a communication from the examining division
04.11.2009Despatch of a communication from the examining division (Time limit: M08)
14.07.2010Reply to a communication from the examining division
26.11.2010Despatch of a communication from the examining division (Time limit: M04)
05.04.2011Reply to a communication from the examining division
10.06.2011Communication of intention to grant the patent
20.10.2011Fee for grant paid
20.10.2011Fee for publishing/printing paid
Divisional application(s)EP10180618.0  / EP2287190
EP10180642.0  / EP2287191
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  14.07.2005
Opposition(s)10.09.2012No opposition filed within time limit [2012/46]
Request for further processing for:10.03.2006Request for further processing filed
10.03.2006Full payment received (date of receipt of payment)
Request granted
24.03.2006Decision despatched
Fees paidRenewal fee
09.12.2002Renewal fee patent year 03
13.05.2003Renewal fee patent year 04
13.05.2004Renewal fee patent year 05
12.05.2005Renewal fee patent year 06
10.05.2006Renewal fee patent year 07
14.05.2007Renewal fee patent year 08
28.03.2008Renewal fee patent year 09
12.05.2009Renewal fee patent year 10
18.05.2010Renewal fee patent year 11
25.05.2011Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT07.12.2011
BE07.12.2011
CY07.12.2011
DK07.12.2011
FI07.12.2011
NL07.12.2011
SE07.12.2011
GR08.03.2012
PT09.04.2012
LU30.05.2012
CH31.05.2012
LI31.05.2012
MC31.05.2012
[2014/27]
Former [2013/29]AT07.12.2011
BE07.12.2011
CY07.12.2011
DK07.12.2011
FI07.12.2011
NL07.12.2011
SE07.12.2011
GR08.03.2012
PT09.04.2012
CH31.05.2012
LI31.05.2012
MC31.05.2012
Former [2013/07]AT07.12.2011
BE07.12.2011
CY07.12.2011
DK07.12.2011
NL07.12.2011
SE07.12.2011
GR08.03.2012
PT09.04.2012
CH31.05.2012
LI31.05.2012
MC31.05.2012
Former [2013/03]BE07.12.2011
CY07.12.2011
DK07.12.2011
NL07.12.2011
SE07.12.2011
GR08.03.2012
PT09.04.2012
MC31.05.2012
Former [2012/49]BE07.12.2011
CY07.12.2011
DK07.12.2011
NL07.12.2011
SE07.12.2011
GR08.03.2012
PT09.04.2012
Former [2012/37]BE07.12.2011
CY07.12.2011
NL07.12.2011
SE07.12.2011
GR08.03.2012
PT09.04.2012
Former [2012/30]BE07.12.2011
CY07.12.2011
NL07.12.2011
SE07.12.2011
GR08.03.2012
Former [2012/28]CY07.12.2011
NL07.12.2011
SE07.12.2011
GR08.03.2012
Former [2012/24]NL07.12.2011
SE07.12.2011
GR08.03.2012
Cited inInternational search[X]  - KIRSCHNING E ET AL, "Primary structure of the antigen-binding domains of a human oligodendrocyte-reactive IgM monoclonal antibody derived from a patient with multiple sclerosis.", JOURNAL OF NEUROIMMUNOLOGY, (1999 SEP 1) 99 (1) 122-30., XP000972985 [X] 1-90 * abstract * * p.125, chapter 3.1 *

DOI:   http://dx.doi.org/10.1016/S0165-5728(99)00118-6
 [X]  - ASAKURA, KUNIHIKO (1) ET AL, "Human IgM from healthy donors enhanced central nervous system remyelination in a murine virus model of multiple sclerosis: A potential novel treatment for multiple sclerosis.", NEUROLOGY, (APRIL 11, 2000) VOL. 54, NO. 7 SUPP. 3, PP. A126-A127. MEETING INFO.: 52ND ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY. SAN DIEGO, CA, USA APRIL 29-MAY 06, 2000 AMERICAN ACADEMY OF NEUROLOGY., XP000973012 [X] 22,25,27,28,33-35,43-49,54,60-62,67-90 * the whole document *

DOI:   http://dx.doi.org/10.1159/000053245
 [DX]  - ASAKURA K ET AL, "Targeting of IgMkappa antibodies to oligodendrocytes promotes CNS remyelination.", JOURNAL OF NEUROSCIENCE, (1998 OCT 1) 18 (19) 7700-8., XP000973031 [DX] 27,28,34,35,43-54,60-62,67-90 * abstract * * page 7701, paragraph L - page 7703, paragraph L *
 [DX]  - MILLER D J ET AL, "A monoclonal autoantibody that promotes central nervous system remyelination in a model of multiple sclerosis is a natural autoantibody encoded by germline immunoglobulin genes.", JOURNAL OF IMMUNOLOGY, (1995 MAR 1) 154 (5) 2460-9., XP000941838 [DX] 27,28,34,35,43-54,60-62,67-90 * abstract * * page 2461, column R *
 [DX]  - SORENSEN P S ET AL, "Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis.", NEUROLOGY, (1998 MAY) 50 (5) 1273-81., XP000973014 [DX] 22,25,27,33,43-49,60-62,67-90 * abstract *
ExaminationUS5591629
    - BANSAL, R. ET AL, J. NEUROSCI. RES., (1988), no. 21, pages 260 - 267
    - MCNULTY, S. ET AL, NEUROSCI. LETT., (1992), no. 139, pages 183 - 187
by applicant   - KIRSCHNING ET AL., J. NEUROIMMUNOLOGY, vol. 99, pages 122 - 130
    - ASAKURA ET AL., NEUROLOGY, vol. 54, no. 3, pages 126 - 127
    - BANSAL ET AL., J. NEURO RES, vol. 21, pages 260 - 267
    - DULBECCO ET AL., VIROL., (1959), vol. 8, page 396
    - NIMAN ET AL., PROC. NATL. ACAD. SCI. USA, (1983), vol. 80, pages 4949 - 4953
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.